Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

APRI 1.61 -0.13 (-7.47%)
price chart
Apricus Biosciences Is Executing Its Strategic Plans (APRI)
For the past few years, Apricus Biosciences, Inc. (NASDAQ:APRI) has attempted to turn its trajectory around and focus on a long-term strategy.
Apricus Biosciences And Vitaros: Update On The Launch (APRI)
It's been almost six months since Vitaros was first launched by Apricus Biosciences (NASDAQ:APRI) in the UK, with follow-up launches in Germany, Sweden and Belgium.
Related articles »  
Apricus Biosciences to Present at the 27th Annual Roth Conference
SAN DIEGO, March 4, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will ...
SeeThruEquity Initiates Coverage on Apricus Biosciences, Inc. with Price ...  Baystreet.ca
Apricus Biosciences: A Screaming Buy Or A Falling Knife?
Apricus Biosciences, Inc. (NASDAQ:APRI) recently began their launch of Vitaros, a topical treatment for Erectile Dysfunction (NYSE:ED), with availability in the UK, Sweden, and now Germany.
Apricus Biosciences' (APRI) CEO Rich Pascoe on Q4 2014 Results - Earnings ...
Apricus Biosciences' (APRI) CEO Rich Pascoe on Q4 2014 Results - Earnings Call Transcript. Mar. 16, 2015 2:03 PM ET | About: Apricus Biosciences, Inc (APRI) by: SA Transcripts. Apricus Biosciences, Inc. (NASDAQ:APRI). Q4 2014 Earnings Conference ...
Apricus Biosciences Provides Corporate Update and 2014 Year-End Financial ...  CNNMoney
Most Volatile Stocks: Sysorex Global Holdings Corp. (SYRX), Apricus ...  WallStreet Scope
Apricus Biosciences Announces Corporate Update and Fourth Quarter and Year ...
Apricus Biosciences, Inc. APRI, -2.14% a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and year-end 2014 financial results will be released on Monday, March ...
Apricus Biosciences' (APRI) CEO Rich Pascoe on Q3 2014 Results -- Earnings ...
Apricus Biosciences' (APRI) CEO Rich Pascoe on Q3 2014 Results -- Earnings Call Transcript. Nov. 10, 2014 12:29 PM ET | About: Apricus Biosciences, Inc (APRI) by: SA Transcripts. Apricus Biosciences, Inc (NASDAQ:APRI). Q3 2014 Earnings Conference ...
Related articles »  
Will Apricus Biosciences (APRI) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Apricus Biosciences Inc (APRI - Snapshot Report). The stock has moved higher by 13.6% in the past month, while it is also above its 20 Day SMA too.
Apricus Biosciences Announces Issuance of U.S. Patent for RayVa(TM)
SAN DIEGO, Jan. 27, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, announced that today, January 27, 2015, the United States Patent and ...
Apricus Bio up on issuance of patent (APRI)  Seeking Alpha (registration)
Apricus Bio up again on robust volume (APRI)
Research firm Taglich Brothers just initiated coverage, after receiving an initial engagement fee of $4,500 from the company for three months' worth of reports.
Apricus Biosciences Coverage Initiated by Analysts at Taglich Brothers (APRI)  sleekmoney